Syros Pharmaceuticals (SYRS) Competitors

Tharimmune (NASDAQ:THAR) and Syros Pharmaceuticals (NASDAQ:SYRS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, community ranking, earnings, dividends, institutional ownership, analyst recommendations, risk, media sentiment and profitability.

Which has better valuation and earnings, THAR or SYRS?

Tharimmune has higher earnings, but lower revenue than Syros Pharmaceuticals. Tharimmune is trading at a lower price-to-earnings ratio than Syros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tharimmune	N/A	N/A	-$9.32M	-$9.74	-0.11
Syros Pharmaceuticals	$386K	1.75	-$164.57M	-$3.03	-0.01

Does the media prefer THAR or SYRS?

In the previous week, Tharimmune had 1 more articles in the media than Syros Pharmaceuticals. MarketBeat recorded 4 mentions for Tharimmune and 3 mentions for Syros Pharmaceuticals. Tharimmune's average media sentiment score of 0.30 beat Syros Pharmaceuticals' score of 0.12 indicating that Tharimmune is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tharimmune	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Syros Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Does the MarketBeat Community prefer THAR or SYRS?

Syros Pharmaceuticals received 365 more outperform votes than Tharimmune when rated by MarketBeat users. However, 100.00% of users gave Tharimmune an outperform vote while only 61.47% of users gave Syros Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Tharimmune	Outperform Votes 2 100.00%	Underperform Votes No Votes
Syros Pharmaceuticals	Outperform Votes 367 61.47%	Underperform Votes 230 38.53%

Do analysts recommend THAR or SYRS?

Tharimmune presently has a consensus price target of $17.00, indicating a potential upside of 1,417.86%. Syros Pharmaceuticals has a consensus price target of $3.33, indicating a potential upside of 13,127.51%. Given Syros Pharmaceuticals' higher possible upside, analysts plainly believe Syros Pharmaceuticals is more favorable than Tharimmune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tharimmune	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.50
Syros Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.20

Do insiders & institutionals have more ownership in THAR or SYRS?

1.2% of Tharimmune shares are owned by institutional investors. Comparatively, 91.5% of Syros Pharmaceuticals shares are owned by institutional investors. 2.4% of Tharimmune shares are owned by company insiders. Comparatively, 12.3% of Syros Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Is THAR or SYRS more profitable?

Tharimmune's return on equity of -167.63% beat Syros Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tharimmune	N/A	-167.63%	-130.18%
Syros Pharmaceuticals	N/A	-3,369.56%	-97.04%

Which has more risk & volatility, THAR or SYRS?

Tharimmune has a beta of 1.18, indicating that its share price is 18% more volatile than the S&P 500. Comparatively, Syros Pharmaceuticals has a beta of 1.31, indicating that its share price is 31% more volatile than the S&P 500.

Summary

Syros Pharmaceuticals beats Tharimmune on 9 of the 16 factors compared between the two stocks.